Arbutus Biopharma Corp
Suletud
4.25 -1.85
Ülevaade
Aktsiahinna muutus
24h
Min
4.17
Max
4.33
Sissetulek | 4M -3.8M |
|---|---|
Müük | 522K 1.1M |
Aktsiakasum | -0.014 |
Kasumimarginaal | -357.374 |
Töötajad | 19 |
EBITDA | 75K -7.6M |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | 26M 865M |
|---|---|
Eelmine avamishind | 6.1 |
Eelmine sulgemishind | 4.25 |
Tehniline skoor
By Trading Central
Kindlus
Weak Bearish Evidence
Arbutus Biopharma Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Arbutus Biopharma Corp Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
